SCHEMBL6497382

SCHEMBL6497382

CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CC(C)NC(C)C4)ccc3OCC)nc12

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 18/20 0.79
PDE3B Q13370 3/20 0.79
PDE3A Q14432 3/20 0.79
PDE2A O00408 1/20 0.79
ABCC4 O15439 1/20 0.79
ABCC5 O15440 1/20 0.79
PDE6D O43924 1/20 0.79
PDE8A O60658 1/20 0.79
PDE9A O76083 1/20 0.79
ABCB11 O95342 1/20 0.79
CYP3A4 P08684 1/20 0.79
HTR1A P08908 1/20 0.79
PDE6A P16499 1/20 0.79
PDE6G P18545 1/20 0.79
PDE4A P27815 1/20 0.79
ADORA2A P29274 1/20 0.79
ADORA1 P30542 1/20 0.79
ADRA1A P35348 1/20 0.79
PDE6B P35913 1/20 0.79
PDE6C P51160 1/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25925162 1.00 PDE5A (0.79) PDE5APDE3BPDE3APDE2AABCC4
SCHEMBL30434848 1.00 PDE5A (0.79) PDE5APDE3BPDE3APDE2AABCC4
SCHEMBL6497379 1.00 PDE5A (0.79) PDE5APDE3BPDE3APDE2AABCC4
SCHEMBL29394704 1.00 PDE5A (0.79) PDE5APDE3BPDE3APDE2AABCC4
SCHEMBL28891471 0.95 PDE5A (0.73) PDE5APDE3BPDE3APDE2AABCC4
SCHEMBL14929265 0.92 PDE5A (0.79) PDE5APDE3BPDE3APDE2AABCC4
SCHEMBL5450733 0.92 PDE5A (0.66) PDE5APDE3BPDE3APDE2AABCC4
SCHEMBL5450729 0.92 PDE5A (0.66) PDE5APDE3BPDE3APDE2AABCC4
SCHEMBL5450646 0.92 PDE5A (0.66) PDE5APDE3BPDE3APDE2AABCC4
SCHEMBL5450606 0.92 PDE5A (0.66) PDE5APDE3BPDE3APDE2AABCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1400522-B1 COMPOUNDS FOR TREATING IMPOTENCE GUANGZHOU YOUCARE BIOPHARMACEATICS CO LTD (CN) 2014-08-06 EP claimed
US-6960592-B2 1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one compound for the treatment of impotence LIU BAOSHUN 2005-11-01 US claimed
US-20040152709-A1 New compound for the treatment of impotence LIU BAOSHUN (CN) 2004-08-05 US claimed
EP-1400522-A1 NEW COMPOUNDS FOR TREATING IMPOTENCE Liu, Baoshun (CN) 2004-03-24 EP claimed
CN-116262118-B Application of alidenafil or salt thereof in preparation of medicines for preventing or treating ischemic brain injury 真奥金银花药业有限公司 2024-03-29 CN disclosed
WO-2023109513-A1 USE OF AILDENAFIL OR SALT THEREOF IN PREPARATION OF MEDICINE FOR PREVENTING OR TREATING ISCHEMIC BRAIN DAMAGE 真奥金银花药业有限公司 2023-06-22 WO disclosed
WO-2023109513-A1 USE OF AILDENAFIL OR SALT THEREOF IN PREPARATION OF MEDICINE FOR PREVENTING OR TREATING ISCHEMIC BRAIN DAMAGE 真奥金银花药业有限公司 2023-06-22 WO disclosed
CN-116262118-A Application of alidenafil or salt thereof in preparation of medicines for preventing or treating ischemic brain injury 真奥金银花药业有限公司 2023-06-16 CN disclosed
US-20230041334-A1 METHODS AND COMPOSITIONS FOR SMOKING CESSATION BEHAVIORAL DIAGNOSTICS, LLC (US) 2023-02-09 US disclosed
EP-1400522-B1 COMPOUNDS FOR TREATING IMPOTENCE GUANGZHOU YOUCARE BIOPHARMACEATICS CO LTD (CN) 2014-08-06 EP disclosed
US-6960592-B2 1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one compound for the treatment of impotence LIU BAOSHUN 2005-11-01 US disclosed
US-20040152709-A1 New compound for the treatment of impotence LIU BAOSHUN (CN) 2004-08-05 US disclosed
EP-1400522-A1 NEW COMPOUNDS FOR TREATING IMPOTENCE Liu, Baoshun (CN) 2004-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152709-A1 New compound for the treatment of impotence PDE3B, PDE3A, PDE5A PDE5A 3/4885PDE3B 1/4885PDE3A 2/4885
US-20230041334-A1 METHODS AND COMPOSITIONS FOR SMOKING CESSATION PDE5A, PDE3A, PDE2A PDE5A 1/4885PDE3B 4/4885PDE3A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.